Yahoo Finance • 10 months ago
-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data... Full story
Yahoo Finance • 2 years ago
Combination of tamibarotene and azacitidine in a Phase 2 trial demonstrated a high complete response rate, with rapid onset and clinically meaningful durability in newly diagnosed unfit acute myeloid leukemia (AML) patients with RARA overe... Full story
Yahoo Finance • 2 years ago
– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – - Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized portion... Full story
Yahoo Finance • 2 years ago
NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story
Yahoo Finance • 2 years ago
CAMBRIDGE, Mass., June 08, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., w... Full story
Yahoo Finance • 3 years ago
There are few stock segments more polarizing than the ‘pennies.’ These are low-cost equities, typically priced below $5 per share, and they elicit two distinct responses from investors. Some buyers can’t get away from the pennies fast enou... Full story
Yahoo Finance • 3 years ago
CAMBRIDGE, Mass., April 01, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an... Full story